Chemodenervating pharmaceutical as anti-inflammatory agent
US7537773B1 · kind B1 · utility
20Cited by
17References
24Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 25, 1999 |
| Grant date | May 26, 2009 |
| Priority date | — |
| Expiry date | Jan 28, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical application of a chemodenervating agent, particularly botulinum toxin, reduces inflammatory response and serves as an anti-inflammatory agent without systemic side effects and with long duration action, on the order of 12-24 weeks. In one embodiment, the effective dosage for allergy provoked inflammation reduction is an order of magnitude less than dosages associated with treatment of regional movement diseases, since the agent works to reduce inflammation by reducing histamine and other preformed mediator releases associated with mast cell degranulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.